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Abstract
Background: Plants have proved to be an important source of anti-cancer drugs. Here we have investigated the cytotoxic
action of an aqueous extract of Fagonia cretica, used widely as a herbal tea-based treatment for breast cancer.
Methodology/Principal Findings: Using flow cytometric analysis of cells labeled with cyclin A, annexin V and propidium
iodide, we describe a time and dose-dependent arrest of the cell cycle in G0/G1 phase of the cell cycle and apoptosis
following extract treatment in MCF-7 (WT-p53) and MDA-MB-231 (mutant-p53) human breast cancer cell lines with a
markedly reduced effect on primary human mammary epithelial cells. Analysis of p53 protein expression and of its
downstream transcription targets, p21 and BAX, revealed a p53 associated growth arrest within 5 hours of extract treatment
and apoptosis within 24 hours. DNA double strand breaks measured as c-H2AX were detected early in both MCF-7 and
MDA-MB-231 cells. However, loss of cell viability was only partly due to a p53-driven response; as MDA-MB-231 and p53-
knockdown MCF-7 cells both underwent cell cycle arrest and death following extract treatment. p53-independent growth
arrest and cytotoxicity following DNA damage has been previously ascribed to FOXO3a expression. Here, in MCF-7 and
MDA-MB-231 cells, FOXO3a expression was increased significantly within 3 hours of extract treatment and FOXO3 siRNA
reduced the extract-induced loss of cell viability in both cell lines.
Conclusions/Significance: Our results demonstrate for the first time that an aqueous extract of Fagonia cretica can induce
cell cycle arrest and apoptosis via p53-dependent and independent mechanisms, with activation of the DNA damage
response. We also show that FOXO3a is required for activity in the absence of p53. Our findings indicate that Fagonia cretica
aqueous extract contains potential anti-cancer agents acting either singly or in combination against breast cancer cell
proliferation via DNA damage-induced FOXO3a and p53 expression.
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Introduction
Following genotoxic stress, an intact DNA damage response
(DDR) is necessary to eliminate lethal and tumorigenic mutations.
The DDR is a network of molecular signalling events that control
and coordinate DNA repair, cell cycle arrest and apoptosis [1]. An
impairment in the DNA damage response represents a double-
edged sword, where on one side loss of repair mechanisms can
drive tumorigenesis and on the other, can affect sensitivity to
genotoxic chemotherapy [2,3].
The tumour suppressor protein, p53, plays a pivotal role in
regulating the cellular response to stress and damage signals.
Several of the cell signalling pathways involved in the DDR and
cell differentiation converge with p53 [4] and loss of p53
functionality is common in more than 50% of cancers [5]. In
response to stress signals, post-translational modifications of p53
such as phosphorylation, drive its nuclear translocation and
subsequent target gene transcription [6,7]. Normally, upon DNA
damage, p53 is rapidly stabilised by the DNA damage sensor,
ATM, via phosphorylation of serine-15 within the p53 N-terminus
activation domain [8]. Consequently, dissociation of the MDM2-
p53 repressor complex, prevents monoubiquitination of p53 and
its degradation [9,10]. This in turn increases p53 half-life and
activates its transcriptional program [11].
Important p53 transcriptional targets include cell cycle control
genes such as p21 (WAF1/CIP1), 14-3-3s and cyclin G, and pro-
apoptotic genes such as BAX [12]. The cyclin dependent kinase
inhibitor, p21, is a direct regulator of the cell cycle, inducing
growth arrest in G1-phase of the cell cycle by binding to and
inhibiting the activity of cyclinD-CDK2/4 complexes [13].
Increased transcription and translation of p21 prevents cyclinD-
CDK2/4 mediated phosphorylation of retinoblastoma protein
(pRb), thus, inhibiting E2F transcriptional activity and cell cycle
progression to S-phase [14].
However, p53-independent growth arrest and cell death has
also been observed following ionizing radiation and DNA damage
(the cell death machinery governed by p53 [15]. Recently, it has
been shown that in response to DNA damage, the transcription
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induction of DNA damage by ionizing radiation, activates
FOXO3a and increases its nuclear translocation. The FOXO3a-
dependent activation of Bim and Fas ligand expression is
associated with induction of apoptosis, and is observed indepen-
dently of p53, highlighting a potential FOXO3a-mediated
response to DNA damage [17]. As well as this, FOXO3a is a
regulator of metabolic homeostasis, via its interaction with Akt and
AMPk signaling pathways [18]. Pharmacological modulation of
these pathways has been shown to induce cell death in cancer cells
via FOXO3a-dependent mechanisms [19,20].
Targeting the cell cycle to induce arrest pharmacologically is
known to be effective in restricting tumour growth in vitro and in
vivo [21,22], particularly in transformed cells that have an
aberrant response to genotoxic and cellular damage [23]. We
have investigated the potential for Fagonia cretica to inhibit the
growth of breast cancer cells via a DNA damage driven response.
Fagonia cretica is a herbaceous plant found in arid, desert regions of
Pakistan, India, Africa and parts of Europe. It is a common plant
used in local medicine as a herbal tea to remedy breast cancer.
However, mechanism(s) of action for Fagonia cretica extracts on
breast cancer cells have not been investigated. Herein, we show
that an aqueous extract of Fagonia cretica induces growth arrest and
apoptosis in human breast cancer cells by inducing DNA damage
and activation of p53 and FOXO3a.
Results
Extract treatment induces cell cycle arrest and apoptosis
in MCF-7 cells
In order to determine whether an aqueous extract of Fagonia
cretica had any cytotoxicity towards normal and breast cancer cells
in vitro, we tested its effects on MCF-7 and MDA-MB-231 cell
viability and cell cycle status, alongside HMEpC. Extract
treatment in the concentration range 0-2mg/ml over 72 hours
induced a significant time and dose dependent reduction in MCF-
7 cell viability (Figure 1A) with an approximate 75% reduction in
cell viability after 72 hours treatment with 2mg/ml aqueous
extract. Similar treatment of MDA-MB-231 cells also induced a
significant time and dose dependent decrease in cell viability
(Figure 1B), with an approximate 67% reduction in cell viability
after 72 hours with 2mg/ml extract. The cytotoxic/static effect of
extract treatment was more pronounced in MCF-7 cells
[IC25=0.43mg/ml] than MDA-MB-231 cells [IC25=1.01mg/
ml] at 24h, although the concentration of active(s) within the
extract is unknown. In parallel, it was shown that an IC25 could
not be reached and only extract treatment of 2mg/ml had any
significant effect on HMEpC viability after 72 hours, with an
approximate 20% reduction in cell viability (Figure 1C). This
suggests greater activity of extract towards human breast cancer
cell lines.
As hyper-proliferation is a characteristic common to tumour
cells, which as a result are more susceptible to cell cycle
modulation, we assessed the effects of extract treatment on
MCF-7 and MDA-MB-231 cell cycle using flow cytometry. We
found that extract treatment could induce a significant increase in
cells expressing low levels of cyclin A associated with G1-phase of
the cell cycle (Figure 2A) with a parallel reduction in G2-phase
cells expressing higher levels of cyclin A (Figure 2B and data not
shown) after 5 hours treatment in MCF-7 cells. This suggests a
potential blockade of cell cycle progression at the G1/S
checkpoint. Extract-treated MDA-MB-231 cells also exhibited a
G1 arrest (Figure 2C) and a parallel reduction in G2-phase cells
(Figure 2D) but induction of G1 arrest was delayed until after
24 hours treatment. Cell cycle checkpoints represent an intersec-
tion of cell survival and cell death where conditions for successful
interphase and mitosis have to be favourable for complete cell
division or the cell commits to death. In accordance with this,
analysis of apoptosis by flow cytometry, was used to determine the
effects of extract treatment on apoptotic induction in MCF-7 cells.
The results revealed a significant increase of annexin V binding in
Figure 1. Fagonia cretica extract treatment reduces breast
cancer cell viability. (A) MCF-7, (B) MDA-MB-231 and (C) HMEpC cells
were treated with up to 2mg/ml aqueous extract for up to 72 hours
prior to analysis of cell viability by MTT assay. Data denoted * (p,0.05)
and *** (p,0.001) are significant at all time points compared to
untreated control analysed by one-way ANOVA with Dunnett’s multiple
comparison post test. Data denoted # (p,0.05) is significant at
72 hours only compared to untreated control analysed by one-way
ANOVA with Dunnett’s multiple comparison post test. All data is
representative of at least three independent experiments performed in
triplicate.
doi:10.1371/journal.pone.0040152.g001
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treatment which increased through to 72 hours (Figure 2E).
Cell cycle arrest is associated with activation of the DNA
damage response
Cell cycle arrest is initiated via activation of the DNA damage
response following genotoxic stress. We used the comet assay to
detect the presence and level of DNA strand breaks in extract-
treated MCF-7 cells. Our results indicate that extract treatment
Figure 2. Fagonia cretica extract induced cell cycle arrest and apoptosis in human breast cancer cells. MCF-7 and MDA-MB-231 cells
were treated with 2mg/ml extract for up to 24 hours prior to cell cycle analysis using cyclin A/propidium iodide staining. (A) G0/G1 MCF-7, (B) G2
MCF-7, (C) G0/G1 MDA-MB-231, (D) G2 MDA-MB-231. (E) MCF-7 cells were treated with 2mg/ml extract for up to 72 hours prior to detection of
apoptosis as annexin V positive/propidium iodide negative stained cells (Q4). Data denoted * (p,0.05), ** (p,0.01) and *** (p,0.001) are significant
compared to controls (time =0) analysed by one-way ANOVA with Dunnett’s multiple comparison post test (n=3 independent experiments). Blots
are representative of at least three independent experiments.
doi:10.1371/journal.pone.0040152.g002
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% DNA present in a comet tail after 3 hours (Figures 3A and 3B),
that is sustained through at least 24 hours (Figures 3A and 3C).
Post-treatment incubation with FPG, a protein that excises 8-oxo-
dG, did not alter the level of DNA damage seen suggesting that
DNA damage is non-oxidative (Figure 3B and 3C). Furthermore
cell survival in the presence of extract was not affected by
pretreatment with the antioxidant N-acetyl-cysteine (data not
shown). Treatment of MCF-7 and MDA-MB-231 cells for up to
24 hours with 2mg/ml extract induced double strand breaks to
DNA as shown by increased levels of c-H2AX over time
(Figure 3D). Induction of the DDR involves sensors such as
ATM relaying a signal to transducers such as p53 to exert cell
cycle arrest via their transcriptional targets. Immunoblotting of
MCF-7 cell lysates after treatment with 2mg/ml extract for up to
24 hours revealed a significant increase in p53 protein expression
as well as increased expression of its transcriptional targets, p21
(Figure 3E) and BAX (Figure 3F), suggesting that extract treatment
is modulating p53-directed cell cycle arrest and apoptosis. In order
to determine if activation of p53 is linked to the presence of DNA
damage we used caffeine, a known inhibitor of ATM/ATR [24],
in combination with extract and assessed p53 and p21 protein
expression. Our results show that inhibition of the DNA damage
sensors ATM/ATR with caffeine prevents the increased expres-
sion of p53 and p21 caused by extract treatment (Figure 4A).
Furthermore, caffeine attenuated some but not all of the extract-
induced cytotoxicity (Figure 4B). Taken together, these results
suggest that extract treatment induces double strand breaks, which
stabilises p53 in an ATM/ATR dependent manner, thus
increasing p53 dependent transcription of p21 and inducing cell
cycle arrest.
Activation of p53 is not essential for loss of cell viability
We have shown that extract treatment of MCF-7 cells induces
DNA damage leading to activation of p53, cell cycle arrest and
apoptosis. The tumour suppressor p53 is mutant in over 50% of
cancers and its loss of function has been shown to be a key event in
neoplasia. We have already shown that the mutant-p53 breast
cancer cell line MDA-MB-231 is susceptible to extract treatment
and that inhibition of extract-induced p53 expression in MCF-7
cells associates with improved cell survival in response to extract
but does not abrogate extract effect completely. In order to verify
the role of p53, we successfully transfected MCF-7 cells (wild-type
p53) with TP53 siRNA and treated them with extract for 24 hours.
Our results show that siRNA knockdown could significantly
reduce an extract-induced increase in p53 expression while
reducing loss of cell viability (Figures 4C and 4D). However, this
did not fully alleviate the effect of extract treatment, providing
further evidence that factors other than p53 are contributing to the
loss of cell viability seen in MCF-7 cells. Taken together, this data
suggests that while p53 activation is occurring in response to DNA
damage, the overall effect of cell cycle arrest and cell death appear
to remain intact, albeit reduced. This suggests that activation of
p53 is important but not essential for cytotoxic activity of extract
treatment.
Extract-induced cytotoxicity is dependent on FOXO3a
expression
The FOX class ‘O’ (FOXO) transcription factors are involved
in the cellular stress response and regulate cell cycle progression
and apoptosis. The FOXO member FOXO3a has been shown to
be vital in the initiation of cell cycle arrest, as well as being
involved in DNA damage mediated apoptosis, independently of
p53. It is also known that FOXO3a is an important tumour
suppressor and is under-expressed in many breast cancers.
Therefore, we hypothesised that extract treatment may increase
FOXO3a expression in MCF-7 and MDA-MB-231 cells resulting
in p53-independent cytotoxicity. Our results show that FOXO3a
expression in both MCF-7 and MDA-MB-231 cells is increased
after 3 hours treatment with 2mg/ml extract (Figure 5A). In both
cell lines this increase peaks at 5 hours and tapers off towards
24 hours treatment. To determine whether or not an extract-
induced increase in FOXO3a was required for cytotoxicity, MCF-
7 and MDA-MB-231 cells were successfully transfected with
FOXO3 siRNA, prior to extract treatment. Knockdown of
FOXO3a expression (Figure 5B and Figure S2) in MCF-7 cells
significantly reduced extract-induced loss of cell viability compared
to extract treatment alone at concentrations above 0.5mg/ml
(Figure 5C). Extract-induced loss of cell viability was still
significant after FOXO3a siRNA transfection probably due to
the p53-mediated effects described previously. In comparison,
knockdown of FOXO3a expression (Figure 5B and Figure S2) in
MDA-MB-231 cells completely abrogated loss of cell viability, in
response to extract treatment (Figure 5D).
Discussion
In this study we report mechanisms of Fagonia cretica aqueous
extract-induced cytotoxicity in breast cancer cells. Local medical
practitioners use Fagonia cretica for treating a wide variety of
ailments, including cancer [25]. This substance is well tolerated
and does not exhibit adverse effects like vomiting, diarrhea or
alopecia, which are common side effects of standard cytotoxic
therapy. To the authors’ best knowledge, this study is the first time
that cytotoxic activity towards human breast cancer cell lines has
been described. Herein, we have shown that an aqueous extract of
Fagonia cretica is able to induce cell cycle arrest and apoptosis in
wild type p53 MCF-7 and mutant p53 MDA-MB-231 cells, while
only exerting a limited effect on primary HMEpC at high
concentrations and extended treatment time. We have also
demonstrated that cell cycle arrest may be associated with
induction of DNA damage and in MCF-7 cells, via activation of
the ATM/p53-mediated DNA damage response. Interestingly, the
requirement of p53 activation is not essential for cytotoxicity, as
we have shown with siRNA p53 knockdown in extract-treated
MCF-7 cells, and the significant treatment effects on mutant-p53
MDA-MB-231 cells. In contrast, extract-induced cytotoxicity is
shown to be dependent on induction of FOXO3a expression, in
both cell types.
Induction of cell cycle arrest occurs in response to various
stresses including DNA damage [26]. Stabilisation and activation
of p53 can occur as a result of serine-15 phosphorylation by
ATM/ATR in the presence of DNA damage [27]. This in turn
allows for p53 nuclear translocation and activation of transcrip-
tional targets such as p21 and BAX to regulate cell cycle control
and apoptosis [28]. According to our results, extract treatment of
MCF-7 cells induced arrest in G1-phase of the cell cycle and
triggered apoptosis, which may be controlled by p53-mediated
transcription of the CDK-inhibitor p21 and pro-apoptotic BAX.
This result is consistent with the literature on tamoxifen which
describes G1-arrest induced by DNA damage in cancer cells [29].
Blockade of extract-induced p53 expression using a phamacolo-
gical inhibitor of ATM/ATR, caffeine, attenuated loss of cell
viability in MCF-7 cells. This suggests activation of the DNA
damage response is driving p53-mediated effects in extract-treated
MCF-7 cells. Indeed, it was further shown that extract treatment
may induce double strand breaks in MCF-7 cells, detectable by
comet assay and by the presence of c-H2AX, however, other
Fagonia cretica-Induced Breast Cancer Cytotoxicity
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H2AX expression. This DNA damage response pathway is well
characterised and provides a potential mechanism by which
extract treatment induces cell cycle arrest and apoptosis in MCF-
7 cells [30,31]. Mutations in p53 that generate a non-functional
phenotype are common in tumours [5], and although frequency is
lower in breast tumours than in other tumour types, mutant status
is associated with a more aggressive disease and mediates tumour
cell survival [32,33]. It is therefore important that drugs are
developed that can specifically target cancer cells independent of
their p53 status. We used siRNA against TP53 to knockdown p53
expression in p53 wild-type MCF-7 cells and then treated the cells
with aqueous extract. Inhibition of p53 expression did reduce the
cytotoxic effect of treatment but did not fully abrogate the loss of
cell viability due to extract treatment. This suggests that p53
mediated cytotoxicity is an additional effect seen in cells that carry
a functional form of p53 but is not vital to the treatment effect. We
confirmed this effect in MDA-MB-231 breast cancer cells, which
carry a mutant, non-functional form of p53. Indeed, we
demonstrated that extract-induced cytotoxicity in MDA-MB-
231 cells is less than in MCF-7 cells but remains significant at
24h. It has been shown previously that cells can arrest in the G1-
phase of the cell cycle independent of the p53-p21 axis [34], and
also that apoptosis can be initiated without p53 activation [35].
Extract-treated MDA-MB-231 cells also underwent G0/G1 arrest
but induction was delayed until 24 hours providing further
support for the notion that p53 expression in MCF-7 cells drives
extract-induced growth arrest. It has been shown previously that
p53 functionality governs kinetics of cell cycle arrest in response to
DNA damage thus providing a mechanism by which absence of
p53 could delay onset of cell cycle arrest [36]. It was evident that
double strand breaks were induced in both MCF-7 and MDA-
MB-231 cells upon extract treatment suggesting a shared mech-
anism driving cell death. Indeed, it has been shown recently that in
response to DNA damage, p53-mutant cells undergo p53-
independent cell cycle arrest and apoptosis, offering a significant
therapeutic strategy for p53-mutant cancers [37].
Members of the forkhead class ‘O’ (FOXO) family of
transcription factors have been implicated in tumorigenesis [38].
In particular FOXO3a has been shown to function as a tumour
suppressor in ERa-positive and negative breast cancers [39,40]. It
has also been reported recently that nuclear localisation of
FOXO3a and subsequent transcriptional activity is a marker of
good prognosis among breast cancer patients [41]. As well as this,
FOXO3a has been show to regulate cell cycle arrest and apoptosis
in response to DNA damage, via activation of transcriptional
targets such as Bim, p27 and Fas-L [17,42]. We report here that
FOXO3a expression is increased in both MCF-7 and MDA-MB-
231 cells in response to extract treatment. Furthermore, suppres-
sion of extract-induced FOXO3a expression using FOXO3
siRNA, attenuated cytotoxicity in MCF-7 cells and completely
abrogated cytotoxicity in MDA-MB-231 cells. Interestingly, levels
of FOXO3a protein expression correlate with time points where
significant DNA damage is exhibited, suggesting FOXO3a
expression may be directly linked to DNA damage. This provides
evidence for FOXO3a-dependent cell cycle arrest and death in
breast cancer cells that works independently of p53 following
extract treatment. Although FOXO3a involvement in oxidative
stress and survival signal withdrawal-induced transcriptional
activity is well documented [43], the role of FOXO3a in response
to DNA damage, is relatively unclear. FOXO3a is activated as a
survival response to energy depletion and can drive autophagy and
apoptosis [44]. Indeed, treatment with Fagonia cretica reduced ATP
levels significantly in MDA-MB-231cells within 3 hours (data not
shown). Energy depletion can occur as a result of excessive PARP
activation due to DNA damage [45]. Therefore, it is possible that
DNA damage may induce a metabolic stress, which directly
activates FOXO3a. Furthermore, FOXO3a driven transcription
of DNA repair genes, including PARP, may further deplete
cellular NAD+ and ATP and lead to cell death [42,46].
Why do HMEpC remain viable following extract treatment
compared to MCF-7 or MDA-MB-231 cells? Cytotoxic agents are
known to induce DNA damage in normal cells as well as cancer
cells. However, fast growing cells are more susceptible to DNA
damaging agents due to the greater probability of more sites being
exposed on DNA within replicative cycles and, in addition, cancer
cells frequently have defective repair pathways resulting in DNA
damage being sustained. While normal cells may also up-regulate
FOXO3a in response to energy depletion and DNA damage, they
are less dependent on glycolytic metabolism than cancer cells.
They may be less energetically challenged in the presence of
Fagonia cretica because of the potential to use oxidative phosphor-
ylation as an additional energy source.
Conclusion
We have shown here for the first time that an extract of Fagonia
cretica induces cell cycle arrest and apoptosis in two phenotypically
distinct breast cancer cell lines. Extract activity involves DNA
damage and p53-induction but is not fully dependent on p53
functionality. In addition, extract treatment induces FOXO3a
expression which may be attributed to DNA damage directly or
induction of DNA repair pathways. We also demonstrated that
FOXO3a expression is required for extract activity in the absence
of functional p53. This provides a novel mechanism by which an
aqueous extract of Fagonia cretica, used extensively in Pakistan, can
kill breast cancer cells in vitro. However, the molecular composition
of the bioactive(s), remains to be determined.
Materials and Methods
Cell culture
MCF-7 (HPA Cultures, UK) and MDA-MB-231 human breast
cancer epithelial cells (HPA Cultures, UK) were cultured in RPMI
1640 with stable glutamine (PAA, UK) supplemented with 10%
FCS and 1% penicillin/streptomycin (50U/ml) and incubated at
37uC with 5% C02. HMEpC cells (Invitrogen, UK) were cultured
in mammary epithelial growth medium (Invitrogen, UK) supple-
mented with growth supplements (Invitrogen, UK; bovine
pituitary extract 0.4% v/v, bovine insulin 5mg/ml, hydrocortisone
0.5mg/ml, human epidermal growth factor 3ng/ml) and 1%
penicillin/streptomycin (50U/ml) and incubated at 37uC with 5%
CO2. Cells were seeded at a density of 2610
5 cells per ml in T75
Figure 3. Fagonia cretica extract treatment induces double strand breaks in human breast cancer cells. MCF-7 cells were treated with
up to 2mg/ml extract for (B) 3 or (C) 24 hours prior to detection of DNA damage using the comet assay with and without FPG protein incubation. (A)
Representative comets after 0, 3 and 24 hour exposure to 2mg/ml extract. (D) MCF-7 and MDA-MB-231 cells were treated with 2mg/ml extract for
24 hours prior to SDS-PAGE and western blot detection of c-H2AX and b-actin. MCF-7 cells were treated with 2mg/ml extract for up to 24 hours prior
to SDS-PAGE and western blot detection of (E) BAX (F) p53, p21 and b-actin. Data denoted * (p,0.05) and *** (p,0.001) are significant compared to
control analysed by one-way ANOVA with Dunnett’s multiple comparison post test.
doi:10.1371/journal.pone.0040152.g003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e40152Figure 4. Fagonia cretica extract-induced p53 expression occurs as a result of activation of the DNA damage response and is only
partly responsible for loss of cell viability. (A, B) MCF-7 cells were treated with and without 3mM caffeine (caff) for 60 minutes prior to up to
2mg/ml extract treatment for up to 24 hours. Expression of p53 and b-actin was determined by SDS-PAGE and western blot. Cell viability was
determined by MTT assay. (C, D) MCF-7 cells were transfected with 10nM TP53 siRNA for 24 hours prior to up to 2mg/ml extract treatment for up to
Fagonia cretica-Induced Breast Cancer Cytotoxicity
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e40152and allowed to reach 80–90% confluence over 7 days prior to sub-
culture.
Fagonia cretica extract preparation and cell treatment
An aqueous extract was prepared by soaking dried plant
material (20g) in 500ml d.H2Oa t7 0 uC for 5 hours with constant
agitation. The extract was filtered with Fisherbrand filter paper
(Fisher Scientific, FB59020, UK) to remove solids before being
subjected to liquid-liquid partition with 3 times equal volumes of
hexane. The aqueous phase was dried under vacuum and stored at
4uC.
Cells were treated for up to 24 hours with 2mg/ml extract prior
to MTT assay or cell lysate collection for SDS-PAGE and western
blot. For caffeine pre-treatment experiments, cells were incubated
with 3mM caffeine for 60 minutes, prior to extract treatment.
24 hours. Expression of p53 and b-actin was determined by SDS-PAGE and western blot. Cell viability was determined by MTT assay. Data denoted
*** (p,0.001) is significant compared to control analysed by one-way ANOVA with Dunnett’s multiple comparison post test. Data denoted ¤
(p,0.001) is significant compared to ‘no-siRNA’ as analysed by two-way ANOVA with Bonferroni’s multiple comparison post test. All data is
representative of at least three independent experiments.
doi:10.1371/journal.pone.0040152.g004
Figure 5. Fagonia cretica extract-induced cytotoxicity is dependent on FOXO3a expression. (A) MCF-7 and MDA-MB-231 cells were
treated with 2mg/ml extract for up to 24 hours prior to FOXO3a protein expression analysis by SDS-PAGE and western blot. b-actin was used as a
loading control. (C) MCF-7 and (D) MDA-MB-231 cells were treated with up to 2mg/ml extract for 24 hours with and without FOXO3 siRNA
transfection (B). Cell viability was determined by MTT assay. Data denoted * (p,0.05), ** (p,0.01) and *** (p,0.001) are significant compared to
untreated control as analysed by one-way ANOVA with Dunnett’s multiple comparison post test. Data is representative of three independent
experiments.
doi:10.1371/journal.pone.0040152.g005
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Validated Silencer TP53 siRNA (Ambion, UK) was used to
knockdown p53 expression in MCF-7 cells. Sequences were: sense
59-GGGUUAGUUUACAAUCAGC(dtdt)-39 and antisense 59-
GCUGAUUGUAAACUAACCC(dtdt)-39. Efficiency of siRNA
knockdown was monitored for effects on cell viability (MTT) and
p53 expression (immunoblot). Transfection controls used Silen-
cerH Negative Control (Ambion. UK, 4404021). 10nM of siRNA
oligonucleotides was incubated in Opti-MEM (Invitrogen, UK) at
a ratio of 1:50 with 1% v/v lipofectamine RNAiMAX (Invitrogen,
UK) and incubated at room temperature for 20 minutes. Cells
were seeded at a density of 1610
5 cells per ml in antibiotic-free
RPMI to tissue culture plates containing siRNA-lipofectamine
duplexes and incubated in cell culture conditions for 24 hours.
Validated Silencer FOXO3 siRNA (Ambion, UK) was used to
knockdown expression MCF-7 and MDA-MB-231 cells. Sequenc-
es were: sense 59-GGCUCCUCCUUGUACUCAAtt-39 and
antisense 59-UUGAGUACAAGGAGGAGCCtg-39 Efficiency of
siRNA knockdown was monitored for effects on cell viability
(MTT) and p53 expression (immunoblot). Transfection controls
used SilencerH Negative Control (Ambion. UK, 4404021).
Methods of siRNA knockdown was as per TP53 siRNA
transfection.
Cell viability – MTT assay
Cell viability was determined using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimet-
ric assay. Cells were seeded at a density of 2610
5 cells per ml in
tissue culture plates and allowed to adhere overnight. Cells were
treated with extract (0–2mg/ml) for up to 72 hours prior to
addition of MTT reagent (0.5mg/ml in PBS) and incubation for
4 hours at 37uC with 5% CO2. Cells were lysed and formazan
solublised over 24 hours with lysis buffer (0.7M SDS, 50% DMF,
pH 4.7) and results determined using a spectrophotometer at
570nm.
Cell cycle analysis – Flow cytometry
Cell cycle status was determined using flow cytometric analysis
and gating against cellular cyclin A levels in combination with
cellular DNA content (Figure S1). Cells were seeded at a density of
2610
5 cells per ml in tissue culture plates and allowed to adhere
overnight. Cells were treated with extract (2mg/ml) for up to
24 hours before cells were washed twice with 1ml PBS and
scraped into 1ml PBS. Cells were pelleted (300g, 5 minutes) and
fixed (1% formaldehyde in PBS) for 20 minutes at room
temperature. Cells were pelleted (300g, 5 minutes) and washed
once with 1ml PBS before being re-suspended in permeabilisation
buffer (0.25% Triton X-100, 0.5% BSA, 50mM PBS) and stored
for 10 minutes at room temperature. Cells were stained with either
anti-cyclin A-FITC (BD Pharmingen, UK) or FITC mouse IgE
isotype control for 50 minutes at room temperature in the dark
followed by propidium iodide staining (10mg/ml, 1% sodium
citrate) for 10 minutes. Cells were washed in permeabilisation
buffer before immediate analysis by flow cytometry (Beckman
Coulter) using FL1 (Em: 525nm) and FL3 (Em: 670nm).
Detection of apoptosis – Flow cytometry
Induction of apoptosis was assessed using flow cytometric
analysis of outer membrane phosphatidylserine translocation. Cells
were seeded at a density of 2610
5 cells per ml in tissue culture
plates and allowed to adhere overnight. Cells were treated with
extract (2mg/ml) for up to 72 hours before washing twice with 1ml
PBS and scraping into 1ml PBS. 1610
5 cells per sample were
stained with annexin V-FITC (Abcam, UK) and propidium iodide
(0.005%) for 5 minutes. Cells were analysed immediately by flow
cytometry using FL1 (Em: 525nm) and FL3 (Em: 670nm).
DNA damage detection – Comet assay
Presence of DNA strand breaks was measured using the single-
cell gel electrophoresis comet assay. Cells were seeded at a density
of 2610
5 cells per ml in tissue culture plates and allowed to adhere
overnight. Cells were treated with 2mg/ml extract for up to
24 hours before washing twice with 1ml PBS and scraping into
1ml PBS. 2610
4 cells were embedded in type VII-A low melting
point agarose on a microscope slide before lysis (100mM
Na2.EDTA, 2.5M NaCl, 10mM Tris-HCl, 1% Triton-X) for
1 hour at 4uC in the dark. Cells were incubated with and without
FPG protein from E. coli (20U/ml) for 30 minutes at 37uC. Slides
were submerged in ice cold electrophoresis buffer (0.3M NaOH,
1mM Na2.EDTA) for 40 minutes at 4uC in the dark before being
subjected to electrophoresis (25V, 300mA) for 30 minutes at 4uC
in the dark. Slides were neutralised (0.4M Tris-HCl, pH 7.5) and
washed with d.H2O before staining with propidium iodide
(150mM PI, 10mM KH2PO4, 150mM NaCl) for 20 minutes at
room temperature in the dark. Comets were visualised and
analysed using COMETscore (http://www.autocomet.com). At
least 50 comets were scored per slide and strand breaks reported as
percentage DNA in comet tail.
Protein characterisation – Western blot
Specific protein expression was measured by western blot. Cells
treated with 2mg/ml extract for up to 72 hours were collected in
lysis buffer (150mM NaCl, 1% Triton X-100, 0.5% SDS, 50mM
Tris-base, 0.1% protease inhibitor cocktail (AEBSF 104mM,
Aprotinin 80mM, Bestatin 4mM, E-64 1.2mM, Leupeptin 2mM,
Pepstatin A, 1.5mM) pH 8.0) and DNA was sheared by passing 10
times through a 25-gauge needle. Protein concentration was
determined using BCA reagent and 25mg total protein used for
western blot. Samples were prepared with Laemmli buffer (1:1 v/
v) and heated at 95uC for 5 minutes before loading into SDS-
PAGE gels (16%). SDS-PAGE was achieved in running buffer
(25mM Tris-base, 190mM glycine, 0.1% SDS) for 120 minutes at
115V. Separated proteins were transferred to Hybond
TM-P
membrane (Amersham, UK) in transfer buffer (25mM Tris-Base,
190mM glycine, 20% methanol) for 70 minutes at 240mA.
Membranes were blocked with 3% BSA in TBS-Tween (50mM
Tris-base, 200mM NaCl, 0.05% Tween-20, pH 7.5) overnight at
4uC. Membranes were probed with primary antibody for 2 hours
in TBS-Tween (0.2% BSA) followed by probing with secondary
detection antibody. Primary antibodies were anti-p53 (Abcam,
ab2433), anti-p21 (Abcam, ab7960), anti-BAX (Abcam, ab7977),
anti-cH2AX (Sigma, H5912), anti-FOXO3a (Abcam, ab47285)
and loading control anti-b-actin (Sigma, A5441). Secondary
antibodies were HRP conjugated anti-mouse IgG (Sigma) and
anti-rabbit IgG (Abcam). Visualisation of bound secondary
antibody was by enhanced chemiluminescence.
Reagents
All reagents are from Sigma unless otherwise stated.
Statistics
Statistical analyses were carried out using one-way ANOVA or
two-way ANOVA with Dunnett’s or Bonfferoni’s multiple
comparison post test. Statistics were calculated using Prism 5.0.
Error bars are representative of the standard deviation.
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Figure S1 Serum starvation and colchicine treatment
induces growth arrest in MCF-7 cells. MCF-7 cells (a)
untreated, (b) serum-starved, or (c) colchicine (0.1mM)-treated for
24 hours were subjected to cell cycle analysis by flow cytometry.
Histograms were generated by plotting log cyclin A-FITC(FL-1)
against propidium iodide (FL-3). A=G0/G1, B=S phase, C=G2
and D=M phase. Data is representative of three independent
experiments performed in duplicate.
(TIF)
Figure S2 Densitometry of FOXO3a expression in
extract treated MCF-7 and MDA-MD-231 cells presented
in figure 5c and 5d. (a) MCF-7 cells and (b) MDA-MB-231 cells
were transfected with and without 5nM FOXO3 siRNA for
24 hours prior to 2mg/ml extract treatment for up to 24 hours.
Cell lysates were collected and FOXO3a protein expression was
assessed by western blot. b-actin was used as a loading control.
Data is expressed as a fold change in FOXO3a density normalised
to b-actin. Data denoted * (p,0.05) and *** (p,0.001) is
significant compared to siRNA treated control (time =0 hours).
Data denoted + (p,0.01) and ++ (p,0.001) is significant
compared to untreated control (time =0 hours). All data was
analysed by one-way ANOVA with Dunnett’s multiple compar-
ison post test. Data is representative of three independent
experiments.
(TIF)
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